A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small bowel tumor cohort.
Chae Young Kwang YK, Dietrich Eliana E, Patel Sandip P SP, Zalupski Mark M et al.
Checkpoint inhibitors have advanced treatment of many cancers. However, their efficacy in many rare tumor types remains unclear; hence, data in these cancers is an unmet need. This paper presents the results of combination therapy with both anti-CTLA and anti-PD-1 in the small bowel cohort of SWOG S1609 dual anti-CTLA-4 & anti-PD-1 blockade in Rare Tumors (DART). DART is a prospective, open-label, multicenter (>1000 sites opened) phase II clinical trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) in rare tumors. DART was conducted through the SWOG Early Therapeutics and Rare Cancers Committee, supported by NCI, and opened at >1000 sites. The primary endpoints included overall response rate (ORR) (RECIST v1.1), complete response (CR) and partial response (PR). Progression-free survival (PFS), overall survival (OS), stable disease (SD) >6 months, and toxicity were secondary endpoints. Twenty-six patients (evaluable, N = 23) were registered. The duodenum was the primary site in 48% (N = 11). The ORR was 9% (CR, 4%, N = 1 (PFS 252 days); PR, 4%, N = 1 (1633+ days); clinical benefit rate (CBR; includes SD > 6 months/PR/CR), 13%. Six-month PFS was 17%; 6-month OS, 50%. Longest responder is ongoing at 1633+ days. The most common toxicities were fatigue and dyspnea (21.7% each), diarrhea and hypothyroidism (17.4% each), with diarrhea, increased bilirubin, colitis and elevated lipase as the most common grade 3-5 immune-related adverse events. Combination therapy with nivolumab plus low-dose ipilimumab in small bowel tumors resulted in a response rate of 9% in 23 treated patients (CBR 13%), including a CR lasting 8 months and a PR ongoing at >4.5+ years. However, the small sample size underpowers meaningful subgroup analysis. Translational studies are needed to identify biologic characteristics that predict response. ClinicalTrials.gov registry: NCT02834013.